<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6532">
  <stage>Registered</stage>
  <submitdate>1/06/2017</submitdate>
  <approvaldate>1/06/2017</approvaldate>
  <nctid>NCT03176238</nctid>
  <trial_identification>
    <studytitle>Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer</studytitle>
    <scientifictitle>A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym>EVEREXES</trialacronym>
    <secondaryid>CRAD001JIC06</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post Menopausal Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - everolimus
Treatment: drugs - exemestane

Experimental: everolimus and exemestane - Everolimus (RAD001) and exemestane combination


Treatment: drugs: everolimus
10 mg tablet will be administered orally once daily on a continuous dosing schedule starting on Day 1

Treatment: drugs: exemestane
25 mg tablet will be administered orally once daily on a continuous dosing schedule starting on Day 1

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of treatment emergent adverse events (Safety and tolerability) - (AEs) by grade (CTCAE, version 4.03), serious adverse events (SAEs), changes from baseline in vital signs and laboratory results (hematology, blood chemistry, lipid profile) qualifying as AEs.</outcome>
      <timepoint>Up to 5 years (Baseline, regularly scheduled visits up to last patient las visit)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate - Objective Response Rate (ORR) is defined as a best overall response of either complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST) (version 1.1)</outcome>
      <timepoint>Up to 5 years (Baseline, regularly scheduled visits up to last patient last visit)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival rate - Progression Free Survival rate (PFS) is defined as the proportion of patients who have not had any documented progression or death due to any cause, according to Response Evaluation Criteria In Solid Tumors (RECIST) (version 1.1).</outcome>
      <timepoint>Up to 5 years (Baseline, regularly scheduled visits up to last patient last visit)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit Rate - Clinical Benefit Rate (CBR) rate is defined as the proportion of patients with best overall response of complete response (CR), partial response (PR) or stable disease (SD), with duration of 24 weeks or longer, according to Response Evaluation Criteria In Solid Tumors (RECIST) (version 1.1)</outcome>
      <timepoint>Up to 5 years (Baseline, regularly scheduled visits up to last patient last visit)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in ECOG performance status - Changes from baseline in ECOG performance status will be described. Time to deterioration of ECOG performance status, from baseline will be assessed using the ECOG Performance Status Scale (Oken, 1982)</outcome>
      <timepoint>Up to 5 years (Baseline, regularly scheduled visits up to last patient last visit)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Postmenopausal women with metastatic, recurrent or locally advanced breast cancer not
             amenable to curative treatment by surgery or radiotherapy.

          -  Histological or cytological confirmation of hormone-receptor positive (HR+) breast
             cancer.

          -  Disease refractory to non-steroidal aromatase inhibitors, defined as:

          -  Recurrence while on, or within 12 months (365 days) of completion of adjuvant therapy
             with letrozole or anastrozole, or

          -  Progression while on, or within one month (30 days) of completion of letrozole or
             anastrozole treatment for locally advanced or metastatic breast cancer (ABC).

          -  Radiological or objective evidence of recurrence or progression on or after the last
             systemic therapy prior to enrolment.

          -  Patients must have:

          -  At least one lesion that can be accurately measured in at least one dimension

               -  20 mm with conventional imaging techniques or = 10 mm with spiral CT or MRI, or

          -  Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as
             defined above.

          -  Adequate bone marrow, coagulation, liver and renal function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients overexpressing HER2 by local laboratory testing (IHC 3+ staining or in situ
             hybridization positive). Patients with IHC 2+ must have a negative in situ
             hybridization test.

          -  Patients with only non-measurable lesions other than bone metastasis (e.g. pleural
             effusion, ascites).

          -  Patients with more than one prior chemotherapy line for ABC. A chemotherapy line is an
             anticancer regimen(s) that contains at least 1 cytotoxic chemotherapy agent, given for
             a minimum of 21 days.

          -  Previous treatment with mTOR inhibitors.

          -  Known hypersensitivity to mTOR inhibitors, e.g. Sirolimus (rapamycin).

          -  Patients with a known history of HIV seropositivity. Screening for HIV infection at
             baseline is not required.

          -  Patient being treated with drugs recognized as being strong inhibitors or inducers of
             the isoenzyme CYP3A

          -  History of brain or other CNS metastases, including leptomeningeal metastasis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>29/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>236</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Garran</hospital>
    <hospital>Novartis Investigative Site - Caringbah</hospital>
    <hospital>Novartis Investigative Site - Liverpool</hospital>
    <hospital>Novartis Investigative Site - Box Hill</hospital>
    <hospital>Novartis Investigative Site - Epping</hospital>
    <hospital>Novartis Investigative Site - Ringwood East</hospital>
    <hospital>Novartis Investigative Site - St Albans</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2229 - Caringbah</postcode>
    <postcode>2170 - Liverpool</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3076 - Epping</postcode>
    <postcode>3135 - Ringwood East</postcode>
    <postcode>3021 - St Albans</postcode>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Gujarat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Orissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Bandung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Jakarta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Jogyakarta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Semarang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state>Amman</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jeollanam-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Taegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Sabah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Morocco</country>
      <state>Casablanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Morocco</country>
      <state>Rabat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan/ Taiwan ROC</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaoshiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state>Ariana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Altunizade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Gaziantep</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kartal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Vietnam</country>
      <state>Ho Chi Minh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The present international, multi-center, open-label, single-arm study aims at collecting
      clinical safety, tolerability and efficacy data with the use of everolimus combined with
      exemestane in the Novartis Oncology Emerging Growth Market (EGM) countries for the treatment
      of post-menopausal women with hormone receptor (HR) positive, human epidermal growth factor
      receptor 2 (HER2) negative locally advanced or metastatic breast cancer after documented
      recurrence or progression following a non-steroidal aromatase inhibitor (NSAI) therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03176238</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>